ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BNTC / earnings
IRD (23) VOGX (45) PRLD (33) ENTA (20) ⌘ Pro Terminal →

Benitec Biopharma Inc. (BNTC) Next Earnings Date & Expected ±12.5% Move

$8.49 -2.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.43

Benitec Biopharma Inc. (BNTC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $304.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.49 (-2.86% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BNTC ranks #795 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BNTC compare to IRD and VOGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNTC?
▼

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $116.9M in revenue (+85.7% YoY), -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.43 (-0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$17 Bull$7 Base$6 Bear
📬 FREE BNTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY BNTC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$8.63+4.8% Next Q
Q2 (-2Q)
35
Grade E$9.04-4% Next Q
Q3 (-1Q)
33
Grade E$8.68-2.2% Next Q
Current
30
Grade E$8.49-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BNTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BNTC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.22) and Max Pain ($8.91) forces dealer call-delta covering toward $17.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BNTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 28, 2026 (~54 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.06 Expected Swing
$7.43 (-12.5%)Spot $8.49$9.55 (+12.5%)
MODEL EARNINGS SETUP GAUGE

BNTC Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-06-30$116.9M-$37.9M-$23.6M52%
FY 20242024-06-30$63.0M-$21.8M-$19.6M52%
FY 20232023-06-30$53.4M-$19.6M-$18.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTC)

  • ✓Walkthrough of BNTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BNTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.30%▼ DESCENDING CHANNEL
2026-11-03O $8.83H $8.83L $8.49C $8.49VOL 135.5K
RES: $13.53SUP: $7.44SMA50: $10.22SMA200: $11.51
$14.78$12.91$11.05$9.18$7.31RES $13.53SUP $7.44$8.492026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BNTC Butterfly Map → + Track BNTC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +85.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BNTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BNTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTC)

Health Care Rank #795 of 1015 ⚔️ IRD vs BNTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BNTC vs. IRD, VOGX, PRLD, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Benitec Biopharma Inc. (BNTC) ranks #795 by composite RQD confidence (30/100, grade E) and #514 by equity capitalization ($304.9M). Within this direct 5-issuer industry benchmark cohort, BNTC leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BNTC at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BNTC ACTIVE
Benitec Biopharma Inc.
E 30/100 — — -35.0% -2.86% $304.9M Benchmark Subject
IRD
Opus Genetics Inc.
E 23/100 — — -35.0% +0.82% $305.3M /ird-vs-bntc →
VOGX
Vogenx Inc
D 45/100 — — — +2.42% $300.8M /vogx-vs-bntc →
PRLD
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -1.03% $309.6M /prld-vs-bntc →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-bntc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001808898 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported GAAP revenue of $116.9M (+85.7% vs. FY2024 revenue of $63.0M , and +118.9% cumulative change since FY2023) , GAAP net income of -$37.9M, operating cash flow of -$23.6M, and free cash flow of -$23.6M (-20.5% YoY). On the balance sheet, BNTC closed FY2025 with $190.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $116.9M -$37.9M -$23.6M -$23.6M $190.7M —
FY2024 (FY) 2024-06-30 $63.0M -$21.8M -$19.4M -$19.6M $79.1M —
FY2023 (FY) 2023-06-30 $53.4M -$19.6M -$18.0M -$18.0M — —

3. BNTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.49 (-2.86% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BNTC ranks #795 in composite RQD confidence.

How does BNTC compare to IRD and VOGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BNTC?

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $116.9M in revenue (+85.7% YoY), -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BNTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BNTC last traded at $8.49 (-2.86% on volume of 240,636 shares), positioning the stock -16.93% below its 50-day simple moving average ($10.22) and -26.24% below its 200-day simple moving average ($11.51). Across its 52-week range of $7.89 to $16.31, BNTC sits at the 7.1% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.43 to $9.55).

Direct Sub-Reports: BNTC RQD Cockpit BNTC 12M Forecast BNTC Earnings & Move BNTC Dividends & DRIP BNTC Insiders & 13F BNTC Whale Options BNTC Profit Sankey BNTC News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

BNTC — Benitec Biopharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Benitec Biopharma Inc. (BNTC) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $8.49 (-2.86% 1D, market capitalization $304.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -7.66%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Benitec Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B. Reported revenue in the SEC financials is — across all listed periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported $116.9M in annual revenue (up from $63.0M in FY2024, +85.7% YoY) and -$37.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($53.4M revenue, -$19.6M net income) through FY2025, BNTC scaled operating cash flow to -$23.6M and free cash flow to -$23.6M, backed by $190.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.66% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $7.89 – $16.31 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Investors should watch whether the pivotal-study regulatory path, referenced in the news feed, affects the company's ability to fund operations given its reported negative free cash flow, since the source does not describe the company's funding structure beyond reported cash.

  • Key Question #1: Can BNTC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $116.9M and free cash flow of -$23.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BNTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BNTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Benitec Biopharma Inc. (BNTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BNTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNTC Bull vs. Bear Conversation Board — What's Your Call at $8.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BNTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $10.75 (+23.0%)
📌 Pinned Debate

Recent news flow includes an FDA regulatory update on the BB-301 pivotal study, an Outperform initiation from Raymond James, and report

The street is overcomplicating Benitec Biopharma Inc. (BNTC). Recent news flow includes an FDA regulatory update on the BB-301 pivotal study, an Outperform initiation from Raymond James, and reported cash rising to $188.8M in FY 2025.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $9.44.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.74 and keeping dry powder in case we test $8.13.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $6.99 (-20.0%)
Spot @ $8.74

The RQD rating of 30 (E) reflects ROIC of -35%, negative free cash flow of -$23.6M in FY 2025, and institutional and insider pillars sc

The RQD rating of 30 (E) reflects ROIC of -35%, negative free cash flow of -$23.6M in FY 2025, and institutional and insider pillars scoring only 3/20 each.. Look at the math on BNTC: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $7.69 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%